Phase I Study of Erlotinib (Tarceva) in Combination With AT-101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

Phase I Study of Erlotinib (Tarceva) in Combination With AT-101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 13 May 2015

At a glance

  • Drugs AT 101; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jun 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 01 Jan 2010 Planned initiation date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 01 Jan 2010 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top